Portolan Capital Management LLC Has $5.30 Million Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Portolan Capital Management LLC raised its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 12.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 749,029 shares of the company's stock after buying an additional 85,427 shares during the quarter. Portolan Capital Management LLC owned 1.23% of Health Catalyst worth $5,296,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Legato Capital Management LLC grew its stake in shares of Health Catalyst by 3.7% in the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company's stock valued at $622,000 after buying an additional 3,171 shares in the last quarter. Quantbot Technologies LP bought a new stake in Health Catalyst in the fourth quarter valued at about $29,000. SG Americas Securities LLC lifted its holdings in shares of Health Catalyst by 21.7% during the fourth quarter. SG Americas Securities LLC now owns 27,382 shares of the company's stock valued at $194,000 after acquiring an additional 4,874 shares during the period. Franklin Resources Inc. raised its stake in shares of Health Catalyst by 5.8% in the third quarter. Franklin Resources Inc. now owns 104,141 shares of the company's stock valued at $857,000 after acquiring an additional 5,687 shares during the last quarter. Finally, Inspire Investing LLC lifted its position in Health Catalyst by 14.2% during the 4th quarter. Inspire Investing LLC now owns 56,379 shares of the company's stock worth $399,000 after buying an additional 7,019 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock.

Health Catalyst Price Performance

Shares of Health Catalyst stock traded up $0.09 during trading on Friday, reaching $3.84. 465,545 shares of the company's stock were exchanged, compared to its average volume of 613,233. The firm's 50-day moving average price is $4.50 and its 200 day moving average price is $6.40. The company has a market cap of $269.61 million, a P/E ratio of -2.84 and a beta of 1.43. Health Catalyst, Inc. has a 1-year low of $3.56 and a 1-year high of $9.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Insider Activity

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total transaction of $30,003.84. Following the transaction, the chief operating officer now directly owns 86,044 shares of the company's stock, valued at approximately $495,613.44. The trade was a 5.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the sale, the general counsel now directly owns 160,437 shares of the company's stock, valued at approximately $729,988.35. The trade was a 7.93 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,588 shares of company stock worth $225,906. Insiders own 2.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Wells Fargo & Company cut their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a report on Tuesday, January 21st. Citigroup reduced their price target on Health Catalyst from $10.50 to $10.00 and set a "buy" rating for the company in a research report on Friday, January 10th. Royal Bank of Canada decreased their price target on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research note on Thursday, February 27th. Stephens cut their target price on shares of Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a research note on Thursday, March 6th. Finally, Canaccord Genuity Group cut their target price on shares of Health Catalyst from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $8.36.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.